Bausch Health Companies Inc. filed SEC Form 8-K: Regulation FD Disclosure

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 22, 2025

Bausch Health Companies Inc.

(Exact name of registrant as specified in its charter)

2150 St. Elzéar Blvd. West

Laval, Quebec

Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

514-744-6792

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

On July 22, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the “Board”) of Bausch Health Companies Inc. (the “Company”), the Board increased the size of the Board from ten to twelve members and appointed Michael Goettler and Sandra Leung, in each case effective as of July 22, 2025. Mr. Goettler will serve on the Talent and Compensation Committee and Science and Technology Committee. Ms. Leung will serve on the Nominating and Corporate Governance Committee.

In connection with their appointments to the Board, pursuant to the Company’s non-employee director compensation policy, each of Mr. Goettler and Ms. Leung will be eligible to receive an annual cash retainer and a director equity grant, in each case as described under “Corporate Governance-Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 2, 2025.

There are no arrangements or understandings between Mr. Goettler or Ms. Leung and any other person pursuant to which there were selected as directors, and there are no transactions related to the Company in which Mr. Goettler or Ms. Leung have an interest requiring disclosure under Item 404(a) of Regulation S-K.

On July 24, 2025, the Company issued a press release announcing the appointments of Mr. Goettler and Ms. Leung. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

The information in the preceding paragraph, as well as Exhibit 99.1 hereto, is being “furnished” pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any Company filing, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing and regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 24, 2025